Innovating Works
SC1-PM-20-2017
SC1-PM-20-2017: Methods research for improved health economic evaluation
Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle significant challenges with limited resources. Many changes are taking place including demographics and burdens of disease, advances in biomedical research, health technologies and personalised medicine, and the availability of large, population-based data sets. These changes highlight the need and potential to develop new or improved methods for economic evaluation, including in the context of Health Technology Assessment and Health Systems Performance Assessment, to support decision-making.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 11-04-2017.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle significant challenges with limited resources. Many changes are taking place including demographics and burdens of disease, advances in biomedical research, health technologies and personalised medicine, and the availability of large, population-based data sets. These changes highlight the need and potential to develop new or improved methods for economic evaluation, including in the context of Health Technology Assessment and Health Systems Performance Assessment, to support decision-making.

While health economics research has generated evidence of differences between costs and health outcomes within and across countries, our understanding of major drivers of these differences is limited. Data on costs and health outcomes are available from an increasing range of sources, underlining the need for better data integration and synthesis of evidence. The challenge is to strengthen data generation for health economic evaluation, the methodological quality of the evaluations and their use in decision-making.


Scope:Proposals... ver más

Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle significant challenges with limited resources. Many changes are taking place including demographics and burdens of disease, advances in biomedical research, health technologies and personalised medicine, and the availability of large, population-based data sets. These changes highlight the need and potential to develop new or improved methods for economic evaluation, including in the context of Health Technology Assessment and Health Systems Performance Assessment, to support decision-making.

While health economics research has generated evidence of differences between costs and health outcomes within and across countries, our understanding of major drivers of these differences is limited. Data on costs and health outcomes are available from an increasing range of sources, underlining the need for better data integration and synthesis of evidence. The challenge is to strengthen data generation for health economic evaluation, the methodological quality of the evaluations and their use in decision-making.


Scope:Proposals should provide new or improved methods for one or both of the following areas:

Understanding variations in costs and health outcomes within and across countries Integrating data on costs and health outcomes from different sources In terms of understanding variations in costs and health outcomes within and across countries, proposals should address which factors on the supply and demand side of a health system have major effects on the costs and outcomes of health-related interventions. This includes methods for more robust measures of wellbeing and quality of life, patient preferences, and experience, patient-reported outcomes, as well as methods for measuring broader economic and societal impacts such as on productivity. In the development of these methods, the perspectives of different important stakeholder groups in the health system and the broader economy should be taken into account.

With respect to data integration, proposals should develop improved or new methods to integrate data on direct and indirect costs of illness and on health outcomes from various sources, such as randomised controlled trials, observational studies, registries, surveys, routine administrative databases including social service records and eHealth[1]. New methods should make use of the strengths of real-world data, while addressing their limitations. The development of new frameworks and models for integrating data sets from different sources should facilitate a continuous and informative assessment of health technologies, services and systems over time.

The research design should be developed by means of a multidisciplinary approach, integrating quantitative and qualitative methods and taking advantage of recent methodological developments in economics. Rigorous standards of health economic research should be applied, including the analysis of underlying assumptions. Research should consider aspects related to gender, socioeconomic status and other health determinants as well as issues related to data protection and relevant regulatory developments, as relevant. The methods to be developed should be applicable to a wide range of health-related interventions spanning prevention and treatment. Furthermore, methods to be developed should take into account the diversity of health systems within and across countries. Research proposals should establish synergies with other relevant research projects and initiatives.[2] Finally, methods and approaches should be validated, with a view to ensuring their applicability, including for routine use in health systems, and their suitability for addressing the above-mentioned changes and challenges faced by health systems.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected Impact: Validated improved or new approaches for the collection and analysis of data for health economic evaluation, resulting in high-quality and comparable information within and across countries Validated improved or new approaches for integration of data from all relevant sources, to facilitate an informative and continuous assessment of health interventions and systems Validated improved or new indicators, measures and tools, to be used by decision-makers for resource allocation in health systems that are patient-centred, efficient and sustainable.
Cross-cutting Priorities:Socio-economic science and humanities


[1]eHealth is the use of ICT in health products, services and processes combined with organisational change in healthcare systems and new skills, in order to improve health of citizens, efficiency and productivity in healthcare delivery, and the economic and social value of health. eHealth covers the interaction between patients and health-service providers, institution-to-institution transmission of data, or peer-to-peer communication between patients and/or health professionals.

[2]Examples include SC1-PM-18-2016 and the IMI2 Big Data for Better Outcomes Programme (BD4BO)

ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle significant challenges with limited resources. Many changes are taking place including demographics and burdens of disease, advances in biomedical research, health technologies and personalised medicine, and the availability of large, population-based data sets. These changes highlight the need and potential to develop new or improved methods for economic evaluation, including in the context of Health Technology Assessment and Health Systems Performance Assessment, to support decision-making. Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle significant challenges with limited resources. Many changes are taking place including demographics and burdens of disease, advances in biomedical research, health technologies and personalised medicine, and the availability of large, population-based data sets. These changes highlight the need and potential to develop new or improved methods for economic evaluation, including in the context of Health Technology Assessment and Health Systems Performance Assessment, to support decision-making.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
 
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in some Horizon 2020 topics (to check funding conditions, follow the links to Australia, Brazil, Canada, China, Hong Kong & Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan, USA*).
*Note that US participants in projects under the Horizon 2020 "Health, Demographic Change and Wellbeing" Societal Challenge are automatically eligible for EU-funding according to the provisions in the relevant work programme
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions: The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.
3.2 Submi...
Please read carefully all provisions below before the preparation of your application.
 
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in some Horizon 2020 topics (to check funding conditions, follow the links to Australia, Brazil, Canada, China, Hong Kong & Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan, USA*).
*Note that US participants in projects under the Horizon 2020 "Health, Demographic Change and Wellbeing" Societal Challenge are automatically eligible for EU-funding according to the provisions in the relevant work programme
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions: The thresholds for each criterion in a single stage process will be 4, 4 and 3. The cumulative threshold will be 12.
3.2 Submission and evaluation process: Guide to the submission and evaluation process
      
Indicative timetable for evaluation and grant agreement:
Information on the outcome of single-stage evaluation: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
 
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Specific evaluation form
H2020 General MGA -Multi-Beneficiary
Annotated Grant Agreement
Essential information for clinical studies
 
Additional provisions:
Horizon 2020 budget flexibility
Classified information
 
Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
- Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs.
- Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
 
Additional documents:
H2020 Work Programme 2016-17: Health, demographic change and wellbeing
H2020 Work Programme 2016-17: Dissemination, Exploitation and Evaluation
H2020 Work Programme 2016-17: General Annexes
Legal basis: Horizon 2020 - Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-SC1-2016-2017 Methods research for improved health economic evaluation Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle signific...
Sin info.
SC1-PM-11-2016-2017 Clinical research on regenerative medicine
en consorcio:
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
SC1-PM-20-2017 Methods research for improved health economic evaluation
en consorcio: Specific Challenge:Health systems need to be resilient. They must be able to adapt effectively to changing environments, and tackle signific...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
SC1-PM-03-2017 Diagnostic characterisation of rare diseases
en consorcio: Specific Challenge:Rare diseases are diseases which affect not more than 5 per 10 000 persons in the European Union. It is estimated that ra...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
SC1-PM-16-2017 In-silico trials for developing and assessing biomedical products
en consorcio: Specific Challenge:In biomedical, pharmaceutical and toxicology research, the safety and efficacy of biomedical products is ultimately teste...
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de
SC1-PM-19-2017 PPI for uptake of standards for the exchange of digitalised healthcare records
en consorcio: Specific Challenge:The use of interoperability standards is essential to the wider deployment of an EU eHealth single market. Despite previo...
Cerrada hace 8 años | Próxima convocatoria prevista para el mes de